Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...

Since 1941, when Gregg first described the triad of deafness, cataracts and cardiac disease as the classical clinical manifestations of congenital rubella syndrome (CRS), strong efforts have been ...

Background: Congenital rubella syndrome (CRS) is associated with several negative outcomes, including autism spectrum disorders (ASDs). The objective of this study was to estimate the numbers of ...

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Cabaletta Bio’s financials and CAR T-cell therapy show potential but face risks. Discover why CABA stock is a risky yet ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Panelist discusses how talquetamab’s step-up dosing strategy aims to mitigate cytokine release syndrome, a common immunologic toxicity. The reported grade 1 CRS with altered taste and dry mouth ...

After hours: January 7 at 6:53:22 PM EST Loading Chart for CRS ...

Cancer immunotherapies are highly effective treatments for treating hematological malignancies, but usually tied to systemic toxicity, including cytokine release syndrome (CRS). POLB-001 reduces ...

Of the 57 patients, 18 (31.6%) developed cytokine release syndrome (CRS) and two had immune effector cell–associated neurotoxicity syndrome (ICANS). All CRS and ICANS resolved, and all patients ...